← Stock Trading Canary · All insider profiles
INSIDER PROFILE · SE
Magnus Christensen
Ekonomichef/finanschef/finansdirektör
Profile key: se|magnus christensen
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 3
- Purchases · 24M
- 3
- Average purchase
- SEK 85,353
- Gross purchase value
- SEK 256,060
- Last purchase
- 2026-05-15
- Completed 20D events
- 3.0
- Outcome status
- INSUFFICIENT_SAMPLE
Latest company: Cinclus Pharma Holding AB (publ)
Companies: Cinclus Pharma Holding AB (publ) | Medivir AB
Post-purchase outcomes
Benchmark-relative outcomes are available against OMX Stockholm 30.
- Excess return = stock return − OMX Stockholm 30 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -3.2% | -4.4% | -10.9% |
| 20D | 3Small sample | 100.0% (3/3) | 0.0% (0/3) | -6.3% | -10.7% | -25.8% |
| 60D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -6.6% | +63.1% | -32.4% |
| 120D | 2Small sample | 100.0% (2/2) | 50.0% (1/2) | +120.2% | +120.2% | -29.1% |
Research patterns
- First purchase in 12M
- 2/3
- Large purchase ≥ €100k
- 0/3
- Cluster buying · 15D
- 0/3
- Buying the dip · ≥20% below prior 52W high
- 2/3
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.